H-L-Thr(tBu)-OMe*HCl

H-L-Thr(tBu)-OMe*HCl is a protected threonine derivative presented as the hydrochloride salt, featuring the L-stereochemistry at the amino acid chiral center and a tert-butyl-protected side-chain hydroxyl (Thr(tBu)) alongside a methyl ester (Thr-OMe). The molecule contains an ammonium functionality under salt conditions, a carboxylate masked as an ester, and a bulky tert-butyl group that modulates hydrogen-bonding and prevents side-chain participation during peptide coupling. This protection pattern supports controlled peptide building-block chemistry by limiting undesired side reactions from the threonine hydroxyl while maintaining a reactive N-terminus suitable for amide bond formation after appropriate activation. The ester and salt form also influence solubility and downstream deprotection planning, making the compound a practical chiral amino acid intermediate for protected amino acid synthesis and peptide construction workflows.

1. Protected Amino Acids

H-L-Thr(tBu)-OMe*HCl serves as a protected amino acid intermediate for preparing peptide building blocks and chiral derivatives in synthetic organic chemistry. The tert-butyl-protected threonine side-chain hydroxyl and the methyl ester C-terminus protect functional groups that would otherwise compete in coupling or rearrangement steps. Salt formation as the hydrochloride can improve handling and can be used to define the amine reactivity window when converting the amino group into an acylation-ready form. Downstream processing commonly involves ester hydrolysis or transesterification and controlled deprotection of the tert-butyl group to reveal the free threonine alcohol for further functionalization, enabling structured access to threonine-containing peptides and analogs.

2. Peptide Synthesis

H-L-Thr(tBu)-OMe*HCl supports peptide coupling strategies where threonine side-chain hydroxyl tolerance is required during chain assembly. The protected alcohol (tBu) reduces the risk of side reactions such as O-acylation or uncontrolled hydrogen-bonding during activation of the amino group and formation of new amide bonds. The methyl ester provides a defined C-terminal functionality that can be converted into an acid or activated derivative for iterative peptide construction or for preparing C-terminal threonine motifs. The L-configuration at the stereocenter enables stereochemically consistent peptide analogs, and the deprotection-ready side chain supports subsequent incorporation into peptide libraries and sequence-defined biomolecule scaffolds.

3. Side-Chain Functionalization

H-L-Thr(tBu)-OMe*HCl is suitable for side-chain functionalization workflows that begin from a protected threonine alcohol and proceed through selective unveiling or transformation. The tert-butyl group masks the hydroxyl, allowing chemoselective manipulation of the amino acid framework while preserving the chiral center for stereochemically defined downstream products. After appropriate deprotection planning, the regenerated threonine hydroxyl can be employed for derivatization routes that generate O-linked handles for conjugation, affinity tags, or chemical probes. The protected ester form further supports staged synthetic sequences where C-terminal activation and side-chain modification can be scheduled to match the requirements of peptide analog construction and chemical biology reagent generation.

4. Chemical Biology Probes

H-L-Thr(tBu)-OMe*HCl can be applied in chemical biology research to generate threonine-containing molecular probes and substrate analogs for studying phosphorylation-relevant motifs or alcohol-reactive labeling chemistries. The protected threonine side-chain hydroxyl enables controlled installation of functional groups after deprotection, supporting the synthesis of hydroxy-functional linkers, clickable handles, or reporter-bearing derivatives. The amino acid backbone configuration and protected group pattern help maintain stereochemical fidelity when probes are incorporated into peptide-like structures or used as building blocks for biomolecule modification. Downstream utility includes preparing labeled peptide fragments for analytical studies, reagent standards for method development, and intermediate scaffolds that feed into larger conjugation schemes.

5. Pharmaceutical Intermediate Preparation

H-L-Thr(tBu)-OMe*HCl is relevant to pharmaceutical intermediate preparation where protected amino acid building blocks are required for manufacturing-grade peptide intermediates and peptidomimetic fragments. The combination of an N-functionalized threonine framework (as a hydrochloride salt), a protected side-chain hydroxyl, and a methyl ester C-terminus supports route design that separates protection, coupling, and deprotection steps to manage reactivity in process chemistry. The stereodefined L-amino acid center supports consistent formation of stereochemically defined intermediates used in downstream synthesis of peptide-like active ingredients or process intermediates. The compound's protection strategy aligns with scalable synthetic planning for fine chemical synthesis, enabling systematic conversion into acids, activated derivatives, or free alcohol threonine motifs used in controlled manufacturing sequences.

6. Analytical Research Standards

H-L-Thr(tBu)-OMe*HCl can function as a chiral analytical reference material precursor for method development in amino acid and peptide analysis. The distinct protected-group pattern, including tert-butyl-protected hydroxyl and methyl ester, provides characteristic chemical signatures that can aid in LC-MS, chiral HPLC, or derivatization-based workflows when monitoring protected amino acid intermediates. Salt formation as the hydrochloride can influence chromatographic behavior and sample preparation consistency for analytical studies tracking deprotection or ester conversion. Downstream formation of deprotected threonine derivatives from this intermediate supports validation of analytical methods that distinguish stereoisomers and functional-group states across peptide synthesis and peptide analog manufacturing pipelines.

1. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

2. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

3. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

4. Myotropic activity of allatostatins in tenebrionid beetles

5. Emu oil in combination with other active ingredients for treating skin imperfections